Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in i ...

EXHIBIT 99.1 ImmunityBio Reports Third-Quarter 2024 Financial Results CULVER CITY, Calif.—Nov. 12, 2024—ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the thirdquarter ended September 30, 2024. ® • ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. • ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). Immu ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company. Immunit ...

ImmunityBio (IBRX) shares soared 26.4% in the last trading session to close at $5.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced the dosing of the first patient in a phase I study evaluating its CAR-NK cell therapy, CD19 t-haNK, for treating relapsed B-cell non-Hodgkin lymphoma. This might have driven the share price rally.This immunotherapy company is expecte ...

EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases. In April this year, the FDA approved ImmunityBio's Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The analyst writes, "Anktiva has the potenti ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio. It has been roughly four months since my last ImmunityBio (NASDAQ: IBRX ) article , where I discussed ANKTIVA's (N-803) commercial launch for BCG-unresponsive non-muscle invasive bladder cancer. It appeared that ImmunityBio had positioned ANKTIVA for r ...

I last covered ImmunityBio (NASDAQ: IBRX ) in October, a few hours before news came out that it resubmitted its BLA for its lead molecule Anktiva for BCG-unresponsive NMIBC (non-muscle invasive bladder cancer) CIS (carcinoma in situ). My timing wasn't right. IBRX is down 21% from an About the TPT service ing Balance (millio Projected American Shared Revenue Backlog $250 $213 $200 $150 $106 $104 $101 $100 $50 $0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This chart includes projecte ...

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.16 per share when it actually produced a loss of $0.20, delivering a surprise of -25%. Over the last four quarters, the company h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 | --- | --- | |----------------------------------------------------------------------------------------- ...

NEW YORK, July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. Why Your Participation Matters: For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. SOURCE Kuehn Law, PLLC If you own ...